4507:TYO
Shionogi & Co Ltd
2.744,50 JPY
arrow_downward
−0,88%(−24,50) 1D
9. lis, 15:30:00 GMT+9 · JPY
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 4507...
Otvori
2.758 JPY
Najviša
2.778 JPY
Najniža
2.734 JPY
Trž. kap.
2,44 bil.
Prosj. kol.
2,93 mil.
Količina
3,31 mil.
Dividenda
2,59 %
Kvartalna dividenda
18 JPY
Datum nakon isplate dividende
29. ruj 2026.
P/E omjer
8,86
52-tjed. najviša
3.758 JPY
52-tjed. najniža
2.392 JPY
EPS
310 JPY
Dionice u optjecaju
314,50 mil.
Broj djelatnika
6 tis.
Otvori
2.758 JPY
Najviša
2.778 JPY
Najniža
2.734 JPY
Trž. kap.
2,44 bil.
Prosj. kol.
2,93 mil.
Količina
3,31 mil.
Dividenda
2,59 %
Kvartalna dividenda
18 JPY
Datum nakon isplate dividende
29. ruj 2026.
P/E omjer
8,86
52-tjed. najviša
3.758 JPY
52-tjed. najniža
2.392 JPY
EPS
310 JPY
Dionice u optjecaju
314,50 mil.
Broj djelatnika
6 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Simply Wall Street
·
prije 7 sati
Shionogi (TSE:4507) Weighs IntraBio Deal, Is The Stock Undervalued?
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Shionogi & Co Ltd – informacije
Glavni izvršni direktorIsao Teshirogi
Zaposlenici6,22 tis.
Osnovano1878
Sjedište-
Sektor-
Web-lokacijashionogi.com